AMCIL Posts 3.6% Increase in Annual Profit Despite Portfolio Lagging ASX 200 by 17.2 Points

AMCIL Faces Portfolio Challenges Amid Sector Rotation and Technology Sector Declines

For the financial year ending 30 June 2026, AMCIL’s portfolio returned negative 10.0% including franking credits, significantly underperforming the S&P/ASX 200 Accumulation Index’s 7.2% return over the same period. The company cited a challenging year marked by wide sector return disparities. The market’s strong performance was largely driven by the Resources sector, where AMCIL maintained a substantial underweight position, negatively impacting relative returns.

Further underperformance stemmed from AMCIL’s overweight positions in the Health Care and Information Technology sectors, which were among the worst-performing sectors. Health Care declined 36.2%, while Information Technology dropped 37.0%. Major holdings in Health Care such as CSL, Cochlear, and ResMed experienced significant share price declines following subdued earnings outlooks. The Information Technology sector suffered a sharp valuation de-rating amid growing market concerns about long-term disruption from artificial intelligence, affecting holdings including WiseTech Global, REA Group, Netwealth, and Objective Corporation.

Modest 1.4% Revenue Growth Reflects Difficult Operating Environment

Revenue from ordinary activities, excluding capital gains, increased slightly by 1.4% to $9.3 million in the year ended 30 June 2026, up from $9.1 million in the prior period. This modest growth reflects the challenging investment environment, with portfolio companies across various sectors facing earnings pressures from macroeconomic and sector-specific headwinds. The company did not provide a detailed revenue breakdown by sector or investment type.

Despite the revenue increase, the portfolio’s market value decline led to a significant drop in net tangible assets per share to $1.08 from $1.29 at the prior year-end, before accounting for any final dividend. This highlights the impact of equity market fluctuations on AMCIL’s asset base amid portfolio performance challenges.

Profit Rises 3.6% Despite Negative Portfolio Returns

AMCIL’s net profit attributable to members rose 3.6% to $6.9 million compared to $6.7 million in the previous corresponding period, despite the portfolio delivering negative returns. This indicates that earnings from portfolio companies and other income sources partially offset unrealised investment losses. The results are based on financial statements undergoing audit at the time of the announcement.

The profit growth reflects AMCIL’s diversified revenue streams, including dividends and distributions from portfolio companies, even during periods of valuation pressure. However, the contrast between modest profit growth and negative portfolio returns underscores timing differences between accounting earnings recognition and market-driven equity valuation changes. AMCIL manages a focused portfolio spanning large, mid, and small capitalisation companies.

Dividend Cut to 4.0 Cents Per Share Signals Conservative Capital Management

For the financial year ended 30 June 2026, AMCIL declared fully franked total dividends of 4.0 cents per share, comprising a 2.5 cents final dividend and a 0.5 cents special dividend. Both dividends will be paid on 31 August 2026 to shareholders on the register as of 10 August 2026, with shares trading ex-dividend from 7 August 2026. This represents a notable reduction from the previous year’s total fully franked dividends of 6.5 cents per share, which included a 2.5 cents final dividend and a 3.0 cents special dividend.

The dividend reduction, particularly the special dividend cut from 3.0 cents to 0.5 cents per share, reflects AMCIL’s cautious capital management amid portfolio underperformance. An interim dividend of 1.0 cent per share, fully franked, was paid on 24 February 2026, consistent with the prior year. The Board sourced 1.5 cents per share of the final and special dividends from capital gains, with tax paid or payable by the Group. The pre-tax attributable gain equals 2.14 cents per share, allowing some shareholders to claim a tax deduction. The company confirmed no conduit foreign income component in the dividend.

Dividend Reinvestment and Substitution Plans Offered at Market-Based Pricing

AMCIL provides shareholders with a Dividend Reinvestment Plan (DRP) and a Dividend Substitution Share Plan (DSSP) to facilitate dividend participation. For the current dividend, pricing for both plans will be set at a nil discount to the Volume Weighted Average Price of AMCIL shares traded on ASX and Cboe Australia over the five trading days following the ex-dividend date. Shareholders must notify the registry of participation by 5pm (AEST) on 11 August 2026.

Shares issued under the DRP and DSSP will rank equally with existing shares. These plans offer shareholders flexibility in managing dividend income and reinvestment aligned with their investment goals, with market-based pricing ensuring fair value without discounts.

Net Tangible Assets Fall to $1.08 Per Share Due to Market Value Adjustments

Net tangible assets before deferred tax provisions on unrealised losses stood at $1.08 per share as of 30 June 2026, down from $1.29 per share at the prior year-end, both figures before considering the final dividend. This 16.3% year-on-year decline reflects the significant impact of negative portfolio returns during the financial year and aligns with the 10.0% negative portfolio return recorded.

AMCIL manages a focused portfolio where large, mid, and small cap companies all significantly influence returns. The marked reduction in net tangible assets per share underscores the sensitivity of AMCIL’s share price and asset value to equity market fluctuations and concentrated portfolio holdings. Shareholders should note this figure excludes the final dividend declared.

Portfolio Adjustments Made in Response to Market and Valuation Challenges

During the year ended 30 June 2026, AMCIL reduced the number of stocks in its portfolio and remains active in portfolio adjustments to meet investment objectives. The company exited positions in REA Group and WiseTech Global amid significant share price declines driven by artificial intelligence disruption concerns, where AMCIL had large relative exposure. Macroeconomic weakness also affected holdings sensitive to consumer sentiment, including ARB Corporation, Temple & Webster, and Mainfreight.

As a long-term investor, AMCIL’s management aims to look beyond short-term market sentiment but continuously reviews conviction in companies based on long-term outlooks and valuations. Despite the challenging environment and underperformance, management remains confident in the long-term prospects of many portfolio companies. The company adheres to a disciplined investment philosophy emphasizing quality and valuation discipline while maintaining flexibility to respond to market changes.

Shareholder Webcast and AGM Scheduled Following Results

AMCIL will host a shareholder webcast on Tuesday, 28 July 2026 at 3.30pm (AEST) to discuss the results. Details for accessing the webcast are available on the company’s website at amcil.com.au. This session offers investors direct insights from management on portfolio performance, strategy, and outlook.

The 2026 Annual General Meeting is scheduled for 12.30pm on Thursday, 1 October 2026. Shareholders will receive further participation details separately. These events provide formal and informal opportunities for shareholders to engage with AMCIL’s board and management regarding company performance and strategy.

Sector Performance Divergence Highlights Challenges for Concentrated Portfolio

In the financial year to 30 June 2026, the S&P/ASX 200 Index saw significant sector performance divergence. The Materials sector led with a 52.1% gain driven by strong commodity prices, while Energy rose 14.5%, benefiting from higher oil prices. Defensive sectors such as Consumer Staples and Utilities outperformed amid macroeconomic and geopolitical uncertainty. Conversely, Health Care and Information Technology were the weakest sectors, declining 36.2% and 37.0%, respectively, with major share price drops in CSL, Cochlear, and ResMed impacting Health Care returns.

AMCIL’s concentrated portfolio strategy, designed for long-term outperformance, resulted in significant underweight exposure to the outperforming Resources sector and overweight exposure to the underperforming Health Care and Information Technology sectors. The sharp valuation de-rating in Information Technology due to AI concerns affected multiple holdings. This sector rotation underscores the risks of concentrated portfolios during periods of market rotation and valuation shifts across sectors and themes.